Glimepiride, Empagliflozin, and Sitagliptin With Metformin for Type 2 Diabetes
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 172 participants.
Also called NCT06759922
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 172 participants
- Sponsor
- Registry
-
NCT06759922
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Pakistan
- Registry status
- Completed
Technical summary
Registry record NCT06759922. Randomized; no masking; primary purpose treatment. Start 2025-01-01 (actual); primary completion 2025-03-30 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Glimepiride, Empagliflozin, and Sitagliptin With Metformin for Type 2 Diabetes
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Tab Metformin + Tab Glimepiride
- Intervention (Drug)
- Tab Metformin + Tab Empagliflozin
- Intervention (Drug)
- Tab Metformin +Tab Sitagliptin
- Intervention (Drug)
- Tab Metformin + Tab Empagliflozin + Tab Sitagliptin
- Lead sponsor
- Bahria University
Record details
- Record id
cardio:ct-nct06759922- Content hash
3089cf8effbeeaad7b020798326d3ef972ebabd3cde7c9811fa0be5837062ed2